Maraviroc: integration of a new antiretroviral drug class into clinical practice | Zendy

Linos Vandekerckhove | Zendy; Chris Verhofstede | Zendy; Dirk Vogelaers | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Maraviroc: integration of a new antiretroviral drug class into clinical practice

Author(s) -

Linos Vandekerckhove,

Chris Verhofstede,

Dirk Vogelaers

Publication year - 2008

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkn130

Subject(s) - maraviroc , ccr5 receptor antagonist , drug , virology , medicine , tissue tropism , human immunodeficiency virus (hiv) , tropism , pharmacology , intensive care medicine , virus , immunology , chemokine , immune system , chemokine receptor

Maraviroc (Pfizer's UK-427857, Selzentry or Celsentri outside the US) is the first agent in the new class of oral HIV-1 entry inhibitors to acquire FDA and EMEA approval. It is expected that this drug will be effective only in a subpopulation of HIV-1-infected people, namely those harbouring only the R5 virus. The wide use of this drug is currently hampered by the lack of a readily available R5 virus only determination test (tropism test) and by insufficient scientific insight into the dynamics of R5 and X4 viruses during infection. We discuss the challenges associated with the currently available assay, as well as the potential role of alternative assays.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research